EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineered Glibenclamide-Loaded Nanovectors Hamper Inflammasome Activation in an Ex Vivo Alzheimer’s Disease Model—A Novel Potential Therapy for Neuroinflammation: A Pilot Study

Francesca La Rosa iD, Simone Agostini iD, Elisabetta Bolognesi iD, Ivana Marventano, Roberta Mancuso iD, Franca Rosa Guerini iD, Ambra Hernis iD, Lorenzo Agostino Citterio iD, Federica Piancone, Pietro Davide Trimarchi, Jorge Navarro, Federica Rossetto iD und 6 weitere

Biomolecules · 2025

DOI: 10.3390/biom15081074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Francesca La Rosa und 17 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy. Hauptthemen laut MEDLINE: Glyburide, Alzheimer Disease, Inflammasomes, Neuroinflammatory Diseases. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of University and Research, Italy, Italian Ministry of Health, Fondazione Romeo ed Enrica Invernizzi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammasomes regulate the activation of caspases resulting in inflammation; inflammasome activation is dysregulated in Alzheimer’s disease (AD) and plays a role in the pathogenesis of this condition. Glibenclamide, an anti-inflammatory drug, could be an interesting way to down-modulate neuroinflammation.

Methods

In this pilot study we verified with ex vivo experiments whether a glibenclamide-loaded nanovector (GNV) could reduce the NLRP3-inflammasome cascade in cells of AD patients. Monocytes isolated from healthy controls (HC) and AD patients were cultured in medium, alone or stimulated with LPS + nigericin in presence/absence of GNV. ASC-speck positive cells and inflammasome-related genes, proteins, and miRNAs expressions were measured. The polymorphisms of ApoE (Apolipoprotein E), specifically rs7412 and rs429358, as well as those of NLRP3, namely rs35829419, rs10733113, and rs4925663, were also investigated.

Results

Results showed that ASC-speck+ cells and Caspase-1, IL-1β, and IL-18 production was significantly reduced (p < 0.005 in all cases) by GNV in LPS + nigericin-stimulated cells of both AD and HC. Notably, the NLRP3 rs10733113 AG genotype was associated with excessive inflammasome-related gene and protein expression. GNV significantly down-regulates inflammasome activation in primary monocytes, at least at protein levels, and its efficacy seems to partially depend on the presence of the NLRP3 rs10733113 genotype.

Conclusions

All together, these results showed that GNV is able to dampen inflammation and NLRP-3 inflammasome activation in an ex vivo monocyte model, suggesting a possible role for GNV in controlling AD-associated neuroinflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlyburideAlzheimer DiseaseInflammasomesNeuroinflammatory DiseasesHumansPilot ProjectsNLR Family, Pyrin Domain-Containing 3 ProteinMaleFemaleAgedApolipoproteins EMonocytesCaspase 1Inflammation

Stichwörter der Autor:innen

Alzheimer’s diseaseNLRP3glibenclamideinflammasomeliposomesrehabilitation

Substanzen

GlyburideInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanApolipoproteins ECaspase 1

Autor:innen und Institutionen

  • IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy.
  • Chemistry Department, University of Milan, 20133 Milan, Italy.
  • School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
  • Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.

ORCID-Profile: Francesca La Rosa, Simone Agostini, Elisabetta Bolognesi, Roberta Mancuso, Franca Rosa Guerini, Ambra Hernis, Lorenzo Agostino Citterio, Federica Rossetto, Pierfausto Seneci, Silvia Sesana, Francesca Re, Mario Clerici, Marina Saresella

Förderung

  • Ministry of University and Research, Italy
  • Italian Ministry of Health
  • Fondazione Romeo ed Enrica Invernizzi
  • Ministry of University and Research (MUR)

Zitieren

APA

La Rosa, F., Agostini, S., Bolognesi, E., Marventano, I., Mancuso, R., Guerini, F. R., Hernis, A., Citterio, L. A., Piancone, F., Trimarchi, P. D., Navarro, J., Rossetto, F., Amenta, A., Seneci, P., Sesana, S., Re, F., Clerici, M., & Saresella, M. (2025). Engineered Glibenclamide-Loaded Nanovectors Hamper Inflammasome Activation in an Ex Vivo Alzheimer’s Disease Model—A Novel Potential Therapy for Neuroinflammation: A Pilot Study. Biomolecules. https://doi.org/10.3390/biom15081074

Vancouver

La Rosa F, Agostini S, Bolognesi E, Marventano I, Mancuso R, Guerini FR, et al. Engineered Glibenclamide-Loaded Nanovectors Hamper Inflammasome Activation in an Ex Vivo Alzheimer’s Disease Model—A Novel Potential Therapy for Neuroinflammation: A Pilot Study. Biomolecules. 2025. doi:10.3390/biom15081074

BibTeX
@article{LaRosa2025,
  author = {La Rosa, Francesca and Agostini, Simone and Bolognesi, Elisabetta and Marventano, Ivana and Mancuso, Roberta and Guerini, Franca Rosa and Hernis, Ambra and Citterio, Lorenzo Agostino and Piancone, Federica and Trimarchi, Pietro Davide and Navarro, Jorge and Rossetto, Federica and Amenta, Arianna and Seneci, Pierfausto and Sesana, Silvia and Re, Francesca and Clerici, Mario and Saresella, Marina},
  title = {Engineered Glibenclamide-Loaded Nanovectors Hamper Inflammasome Activation in an Ex Vivo Alzheimer’s Disease Model—A Novel Potential Therapy for Neuroinflammation: A Pilot Study},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15081074}
}
Kostenlos starten →